Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study

Lipids in Health and Disease

Jacek Rysz²  Maciej Banach³  Marek Paradowski¹  Rafał N Wlazeł¹  Anna Stępień²  Mariusz Stępień² 

[1] Department of Laboratory Diagnostics and Clinical Biochemistry, Medical University of Lodz, Lodz, Poland;Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Żeromskiego str. 113, 90-549 Lodz, Poland;Department of Hypertension, Medical University of Lodz, Lodz, Poland

关键词: Obesity indices;    Chronic inflammation;    Hypertension;    Obesity;   

Others  :  811533
DOI  :  10.1186/1476-511X-13-29

 received in 2014-01-23, accepted in 2014-02-05,  发布年份 2014

【 摘 要 】

Background

The aim of this study was to estimate associations between inflammatory markers and obesity indices in normo- and hypertensive subjects.

Methods

65 obese adult subjects were divided into two groups: (A) of hypertensives (n = 54) and (B) of normotensives (n = 11). Waist circumference (WC), body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), visceral adiposity index (VAI), body adiposity index (BAI) and tumor necrosis factor-α (TNF-α), interleukin (IL)-6 and high sensitivity C-reactive protein (hsCRP) serum concentrations were estimated.

Results

In group A WHtR was higher (0.69 ± 0.07 vs 0.63 ± 0.06; p < 0.01), hsCRP correlated with BMI and WHtR (r = 0.343; p = 0.011 and r = 0.363; p < 0.01, respectively). BAI correlated with hsCRP in group A and B (r = 0.329; p < 0.05 and r = 0.642; p < 0.05; respectively) and in females and males (r = 0.305; p = 0.05 and r = 0.44; p < 0.05, respectively). In females hsCRP was higher (3.2 ± 2.2 mg/l vs 2.1 ± 1.5 mg/l; p < 0.05). In patients without lipid lowering treatment hsCRP and IL-6 were higher (3.2 ± 1.7 mg/l vs 2.4 ±2.2 mg/l; p = 0.01 and 15.9 ± 7.2 pg/ml vs 13.6 ± 9.9 pg/ml; p < 0.01, respectively).

Conclusions

WHtR is a sensitive index associated with chronic inflammation in obese hypertensive subjects. BAI correlates with hsCRP independently of hypertension and sex. hsCRP is more sensitive marker associated with obesity than IL-6 and TNF-α. Lipid lowering treatment influence chronic inflammation.

【 授权许可】

   
2014 St¿pie¿ et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bastard JP, Maachi M, Lagathu C, et al.: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Net 2006, 17(1):4-12.
• [2]Patel PS, Buras ED, Balasubramanyam A: The role of the immune system in obesity and insulin resistance. J Obesity 2013, 9 pages. ID 616193, dx.doi.org/10.1155/2013/61693
• [3]Balistreri CR, Caruso C, Candore G: The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediat Inflamm 2010, 19 pages. article ID 802078, doi:10.1155/2010/802078
• [4]Rodríguez-Hernández H, Simental-Mendía LE, Rodríguez-Ramírez G, Reyes-Romero MA: Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol 2013, 11 pages. article ID 678159, dx.doi.org/10.1155/2013/678159
• [5]Fuentes E, Fuentes F, Vilahur G, et al.: Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome. Mediat Inflamm 2013, 11 pages. article ID 136584, doi:10.1155/2013/136584
• [6]de Oliveira Leal V, Mafra D: Adipokines in obesity. Clin Chim Acta 2013, 419:87-94.
• [7]Blüher M: Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Prac Res Clin Endocrinol Metab 2013, 27:163-177.
• [8]Han JM, Levings MK: Immune regulation in obesity-associated adipose inflammation. J Immunol 2013, 191:527-532.
• [9]Fain JN: Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediat Inflamm 2010, 20 pages. ID 513948; doi:10.1155/2010/513948
• [10]Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
• [11]Sell H, Eckel J: Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care 2010, 13:366-370.
• [12]De Heredia FP, Gόmez-Martínez S, Marcos A: Chronic and degenerative diseases. Obesity, inflammation and the immune system. 5th International Immunonutrition Workshop. Proc Nutr Soc 2012, 71:332-338.
• [13]Maury E, Brichard SM: Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010, 314:1-16.
• [14]Coelho M, Oliveira T, Fernandes R: Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 2013, 9:191-200.
• [15]Niskanen L, Laaksonen DE, Nyyssönen K, et al.: Inflammation, abdominal obesity and smoking as predictors of hypertension. Hypertension 2004, 44:859-865.
• [16]Boos CJ, Lip GYH: Is hypertension an inflammatory process? Curr Pharm Design 2006, 12:1623-1635.
• [17]Dagenais NJ, Jamali F: Protective effects of angiotensin II interruption: evidence for anti-inflammatory actions. Pharmacother 2005, 25:1213-1229.
• [18]Stępień M, Wlazeł RN, Paradowski M, et al.: Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. Arch. Med. Sci. 2012, 8:431-436.
• [19]Stepien M, Stepien A, Wlazel RN, et al.: Predictors of insulin resistance in patients with obesity: a pilot study. Angiology 2014, 65(1):22-30.
• [20]Lee CM, Huxley RR, Widma RP, Woodward M: Indices of abdominal obesity are better discrimination of cardiovascular risk factor than BMI: a meta-analysis. J Clin Epidem 2008, 61:646-653.
• [21]Amato MC, Giordano C, Galia M, for the AlkaMeSy Study Group, et al.: Visceral Adiposity Index. A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010, 33:920-922.
• [22]Bergman RN, Stefanovski D, Buchanan TA, et al.: A better index of body adiposity. Obesity 2011, 19:1083-1089.
• [23]Lapice E, Maione S, Patti L, et al.: Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care 2009, 32:1734-1736.
• [24]Arbel Y, Birati EY, Shapira I, et al.: Comparison of different anthropometric measurements and inflammatory biomarkers. Int J Inflam 2012, 2012:124693. doi:10.1155/2012/124693
• [25]Stępień A, Stępień M, Wlazeł RN, et al.: New indices of visceral adiposity and its correlation with hs-CRP in patients with obesity. Clin Exp Med Lett 2011, 52:91-95.
• [26]Pannacciulli N, Cajntatore FP, Menenna A, et al.: C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes 2001, 25:1416-1420.
• [27]Lichtash CT, Cui J, Guo X, et al.: Body adiposity index versus body mass index and anthropometric traits as correlates of cardiometabolic risk factors. PloS ONE 2013, 8(6):e65954.
• [28]Thung-Wei K, Lu IS, Kuo-Chen L, et al.: Associations between body mass index and serum levels of C-reactive protein. S Afr Med J 2009, 99:326-330.
• [29]Engeli S, Feldpausch M, Gorzelniak K, et al.: Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003, 52:942-947.
• [30]Stepien M, Stepien A, Banach M, et al.: New obesity indices and adipokines in normotensive patients and patients with hypertension. Angiology 2013. doi:10.1177/000331971348580
• [31]Karastergiou K, Smith SR, Greenberg AS, Fried SK: Sex differences in human adipose tissues – the biology of pear shape. Biol Sex Differ 2012, 3:13. BioMed Central Full Text
• [32]White UA, Tchoukalova YD: Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta 2014, 1842(3):377-92. dx.doi.org/10.1016/j.bbadis.2013.05.006
• [33]Park HS, Park JY, Yu R: Relationship of obesity and visceral obesity with serum concentrations of CRP, TNF-α and IL-6. Diab Res Clin Pract 2005, 69:29-35.
• [34]Saijo Y, Kiyota N, Kawasaki Y, et al.: Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes, Obesity and Metabolism 2004, 6:249-258.
• [35]Khan R, Haque SF, Quaiser S: The inflammatory markers: C-Reactive Protein and TNF-α predict cardiovascular risk in obese North Indian subjects. Biomed Res 2011, 22:475-480.
• [36]Gharipour M, Sadeghi M, Mansourian M, et al.: Correlation of circulating inflammatory markers, ghrelin, adiponectin with obesity indices in subjects with metabolic syndrome. Pak J Med Sci 2013, 29:264-268.
• [37]Agraval N, Chitrika A, Bhattacharjee J, Jain SK: Correlations of tumor necrosis factor-α and interleukin-6 with anthropometric indices of obesity and parameters of insulin resistance in healthy north Indian population. JIACM 2011, 12:196-204.
• [38]Belfort R, Berria R, Cornell J, Cusi K: Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010, 95:829-836.
• [39]Chan DC, Watts GF, Barrett HR, et al.: Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002, 48:877-883.
• [40]Park OY, Kim SH, Ahn YK, et al.: Statin reduces C-reactive protein and interleukin-6 in normocholesterolemic patients with acute coronary syndrome. Chonnam Med J 2008, 44:13-16.
• [41]Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, Narkiewicz K, Rysz J, Ray KK, Abdollahi M: Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects–a meta-analysis of randomized controlled trials. Int J Cardiol 2013, 168(3):2816-2824.
• [42]Stępień M, Stępień A, Wlazeł RN, Paradowski M, Banach M, Rysz M, Rysz J: Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease. Med Sci Monit 2013, 19:1063-1072.
• [43]Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M: Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011, 7(6):1055-1066.